Medinol , Ltd.

Industry:

Medical Devices & Equipment

Description

Medinol is an expert in the field of stenting and the inventor of the flexible closed cell stent design. Since its establishment in 1992, Medinol has been dedicated to designing novel stents and stenting solutions. Medinol's revolutionary stenting solutions reflect the company's uncompromising commitment to patient-focused therapeutic innovations.

Medinol is distinct in its ability to bring together a broad coalition of disciplines. Its accumulated knowledge base covers the spectrum of scientific, medical, clinical, and technological disciplines. This interdisciplinary in-house know-how enables Medinol to transfer its scientific knowledge into cutting edge stenting solutions.

Every Medinol stent is designed with the optimal qualities clinicians seek and patients need. Medinol's first generation patented NIR® stent revolutionized the interventional cardiology industry with its flexible closed cell design. Medinol's second-generation stent, the NIR® Conformer further moved the industry standards forward. The NIR® family of stents which included stents for both coronary and peripheral applications were exclusively distributed by Boston Scientific Corporation between 1995-2002.

Medinol continues to set new stenting solution standards. Understanding the need for simultaneous flexibility, before and after deployment, and support after deployment, Medinol created the NIRFLEX family of products that dynamically conform in tortuous sections during vessel movements, while maintaining optimal scaffolding. NIRFLEX stent systems are currently available around the globe.

Medinol's intellectual property portfolio includes patents relating to stent design and stent manufacturing. The company's broad intellectual property product portfolio reflects its exceptional capability to design the most advanced and innovative stents in the industry. Through its unique approach to stent manufacturing, Medinol invented breakthrough technology based on etching as opposed to the traditional laser cut method. Medinol's proprietary manufacturing process guarantees the highest level of quality and production reliability.

Products & Services

cardiovascular stents, medical device

View More Statistics

Site Statistics

Monthly Unique Visitors:	633
Site Rank:	1,728,419
Trust Rating:	Neutral
Stats by

News Archive

Federal Circuit Rejects "Medinol" Standard for Proving Fraud on the USPTO.(trademark infringement cases)(Case overview) Mondaq Business Briefing; 9/8/2009 ...published September 1, 2009 Keywords: trademark, Medinol Standard, fraud, USPTO, Medinol v. Neuro Vasx Inc., misrepresentation, should...negligence, Lanham Act, Since its 2003 decision in Medinol v. Neuro Vasx, Inc., 67 U.S.P.Q.2d... ...more

Federal Circuit Overrules Medinol; Fraud Requires Clear And Convincing Evidence Of Intent To Deceive.(Case overview) Mondaq Business Briefing; 9/7/2009 ...fraud doctrine decision set forth in Medinol, Inc. v Neuro Vasx Inc., 67 USPQ 2D 1205 (TTAB 2003). In Medinol and its progeny, the Board articulated...be false or misleading. In overruling Medinol, the Federal Circuit stated: "[b... ...more

Federal Circuit Reverses Medinol Fraud Standard. Mondaq Business Briefing; 11/3/2009 ...Federal Circuit overturned the infamous Medinol trademark procurement fraud standard previously...TTAB's fraud standard articulated in Medinol Ltd. v. Neuro Vasx, Inc, 67 U.S...2d 1205 (T.T.A.B. 2003). In Medinol, the TTAB had ruled that merely filing... ...more